Paper Details

  1. Home
  2. Paper Details

An advance in ophthalmic pharmacology. The use of the epinephrine pro-drug dipivalyl epinephrine in the treatment of glaucoma.

Author: GarziaR

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Dipivefrin, an epinephrine pro-drug, is a valuable treatment for open angle glaucoma due to its effectiveness and lower incidence of side effects compared to epinephrine.
Paper Details　
Original Abstract of the Article :
The development and use of dipivalyl epinephrine, an epinephrine pro-drug, represents a major advance in the pharmacological treatment of open angle glaucoma. Relative to its less lipid soluble parent compound, dipivefrin has been shown in clinical trials to control intraocular pressure effectively ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/7130613

データ提供：米国国立医学図書館（NLM）

Dipivefrin: A New Dawn in Ophthalmic Pharmacology

This research explores a significant advance in ophthalmic pharmacology: the development of dipivalyl epinephrine, a pro-drug of epinephrine, for the treatment of open-angle glaucoma. Dipivefrin, like a beacon in the vast desert of eye care, offers a more effective and well-tolerated treatment option compared to its parent compound, epinephrine. The study found that dipivalyl epinephrine is effective at controlling intraocular pressure at concentrations 10-20 times lower than epinephrine, leading to a reduced incidence of ocular and systemic side effects. This advancement represents a significant improvement in the treatment of glaucoma, offering a more manageable and less burdensome approach.

A New Oasis in Glaucoma Treatment: Dipivefrin

This study unveils the potential of dipivalyl epinephrine as a promising new treatment option for open-angle glaucoma. Its effectiveness at lower concentrations and reduced side effect profile make it a more attractive option for patients seeking relief from glaucoma.

Navigating the Desert of Glaucoma: Choosing the Right Treatment

If you are struggling with glaucoma, consult your ophthalmologist to discuss the most appropriate treatment options. Dipivefrin may be a viable solution, offering a more effective and well-tolerated approach to controlling intraocular pressure.

Dr.Camel's Conclusion

This research marks a significant milestone in ophthalmic pharmacology, introducing dipivalyl epinephrine as a promising new treatment option for open-angle glaucoma. Its effectiveness and reduced side effects offer a brighter future for patients facing this challenging condition.
Date :
  1. Date Completed 1982-12-18
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

7130613

DOI: Digital Object Identifier

7130613

Related Literature

Article Analysis
・Side Effects of dipivefrin ophthalmic
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.